British Journal of Clinical Pharmacology · 1975 · 201 citations · 13 references
PharmacyPharmacologyPharmacotherapyClinical PharmacologyGastrointestinal PharmacotherapyOral Drug DeliveryDrug DispositionGastrointestinal PharmacologyPeptic Ulcer DiseasePeptic Ulcer PharmacotherapyGastric Enzyme SecretionGastric SecretionHistamine H2 Receptor AntagonismHistamine-2 Receptor Antagonist TherapyHistamine-mediated SecretionUnchanged Drug Excretion
Cimetidine, a new H2-receptor antagonist, was safely administered to eighteen healthy man by the intravenous, intraduodenal or oral route. 2 When gastric secretion was maximally stimulated by either histamine or pentagastrin, the simultaneous administration of cimetidine produced marked inhibition of both acid and pepsin secretion. 3 Cimetidine was well absorbed by mouth and had a blood half-life of 2 hours. 4 Cimetidine was rapidly excreted via the kidneys and about 70% of the excreted material was unchanged drug. 5 Clinical evaluation of cimetidine in patients with peptic ulceration is recommended.
13
Metiamide — An orally active histamine H2-receptor antagonist
J. W. Black, W. A. M. Duncan, J. C. EMMETT et al. · Inflammation Research · 1973 · 258 citations
NEUTROPENIA ASSOCIATED WITH METIAMIDE
J. A. H. Forrest, D. J. C. Shearman, Rebecca Spence et al. · The Lancet · 1975 · 83 citations
Medicine, Hematology, Oncology +7
Charles T. Richardson, Beth A. Bailey, John H. Walsh et al. · Journal of Clinical Investigation · 1975 · 75 citations · Full text